A potential new Alzheimer's drug represses the harmful inflammatory response of the brain's immune cells, reducing disease pathology, preserving neurons and improving cognition in preclinical tests.

There has been progress in developing treatments for Alzheimer’s disease that reduce amyloid-beta protein. However, there is a need for treatments that also reduce inflammation as it has been hard to ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, a pioneer in machine learning for drug discovery and development, today announced a new collaboration with Eli Lilly and Company (Lilly) to ...

Genesis’ proprietary foundation model – Pearl – outperforms frontier models, including AlphaFold 3, on key benchmarks that predict utility in real-world drug discovery Pearl’s performance improved ...

Determining correlations between molecules at various levels is an important topic in molecular biology. Large language models have demonstrated a remarkable ability to capture correlations from large ...

In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread. MIAMI, FLORIDA / ACCESS ...

In a new study, a molecule identified and recently synthesized was shown to restore cognitive functions in mice with symptoms of Alzheimer's disease by effectively jump-starting the brain's memory ...

Though drug developers have achieved some progress in treating Alzheimer’s disease with medicines that reduce amyloid-beta protein, other problems of the disease including inflammation, continue ...